In a world first, a bespoke gene-editing therapy benefited one child. Now researchers plan to launch a clinical trial of the approach ...
PCSK9 inhibition may be a suitable alternative for statin-intolerant patients, and recent data demonstrated its efficacy as ...
CRISPR Therapeutics is likely to witness an earnings beat as Casgevy sales climb and new CAR-T and in-vivo programs advance.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback